Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus GENTAMICIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus GENTAMICIN SULFATE.
GENTAK vs GENTAMICIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic